Apogee Therapeutics released Phase 2 maintenance data showing its anti‑IL‑13 candidate zumilokibart maintained EASI‑75 skin responses with far less frequent dosing: 75% of patients on quarterly injections and 85% on biannual dosing sustained at least 75% improvement at one year. The company framed the results as evidence of a longer‑acting profile compared with current biologics. Apogee and STAT noted that larger trials are required to confirm findings; if validated, the agent could challenge Regeneron/Sanofi’s Dupixent and Lilly’s Ebglyss by offering more convenient dosing. EASI‑75 is a standard dermatology endpoint that measures a 75% reduction in extent and severity of lesions.